Bosutinib (rINN/USAN; codenamed SKI-606, marketed under the trade name Bosulif) is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia.
Originally synthesized by Wyeth, it is being developed by Pfizer.
2 Medical uses
6 See also
8 External links
It is an ATP-competitive Bcr-Abl tyrosine-kinase inhibitor with an additional inhibitory effect...